Mapping Organ Health Following COVID-19 Disease Due to SARS-CoV-2 Infection (NCT04369807) | Clinical Trial Compass
CompletedNot Applicable
Mapping Organ Health Following COVID-19 Disease Due to SARS-CoV-2 Infection
United Kingdom693 participantsStarted 2020-04-21
Plain-language summary
A prospective, longitudinal, observational cohort study looking at patients following COVID-19 disease using multi-parametric magnetic resonance imaging (MRI) to assess the degree and prevalence of organ injury.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Male or female 18 years of age and older willing and able to give informed consent to participate in the study
* Recent confirmed diagnosis of SARS-CoV-2 RNA via a polymerase chain reaction (PCR) assay (having been discharged 7 or more days from hospital).
Exclusion Criteria:
* Symptoms of active respiratory viral infection:
* high temperature (over 37.8C/100.04F)
* cough (consistent for over an hour; 3 or more episodes in 24 hours)
* The participant may not enter the study with any known contraindication to magnetic resonance imaging (including but not limited to pregnancy, a pacemaker or other metallic unfixed implanted device, metallic fragments, extensive tattoos, severe claustrophobia).
* Any other cause, including a significant underlying disease or disorder which, in the opinion of the investigator, may put the participant at risk by participating in the study or limit the participant's ability to participate.
What they're measuring
1
Characterise prevalence and severity of organ volume change and damage (heart, kidneys and liver)